The latest price target for Biodesix (NASDAQ:BDSX) was reported by Scotiabank on September 16, 2024. The analyst firm set a price target for $3.00 expecting BDSX to rise to within 12 months (a possible 141.94% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ:BDSX) was provided by Scotiabank, and Biodesix initiated their sector outperform rating.

There is no last upgrade for Biodesix

There is no last downgrade for Biodesix.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a initiated with a price target of $0.00 to $3.00. The current price Biodesix (BDSX) is trading at is $1.24, which is within the analyst’s predicted range.